BAJAJ BROKING

Notification
No new Notification messages
Inventurus Knowledge Solutions IPO is Open!
Apply for the Inventurus Knowledge Solutions IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
marksans pharma limited stock

MARKSANS PHARMA LIMITED Share Price

312.25 1.75 (0.56%)
Dec 13 2024 03:30 PM Pharmaceuticals NSE: MARKSANS

MARKSANS PHARMA LIMITED Share Price Update

As of the latest trading session, MARKSANS PHARMA LIMITED share price is currently at 312.25, which is up by 1.75 from its previous closing. Today, the stock has fluctuated between 307.00 and 319.50. Over the past year, MARKSANS PHARMA LIMITED has achieved a return of 92.92 %. In the last month alone, the return has been 2.14 %. Read More...

MARKSANS PHARMA LIMITED Performance

Day Range

Low307.00 High319.50
312.25

52 Week Range

Low 130.00 High 358.70
312.25

MARKSANS PHARMA LIMITED Share Price

10579

524404

MARKSANS

img img img img
No Data Available

Open Price

309.30

Prev. Close

310.50

Volume (Shares)

1831724.00

Total traded value

5719.55

Upper Circuit

372.60

Lower Circuit

248.40

Note: The current prices & values are delayed, Login to your account for live updates.

MARKSANS PHARMA LIMITED Fundamentals


(Standalone)

Market Cap (Cr) 14150.04
PE Ratio (TTM) 92.15
Book Value / Share 28.48
Beta 0.94
ROE 11.46%
EPS (TTM) 3.39
Dividend Yield 0.19%
Net Profit Qtr (Cr) 63.20

MARKSANS PHARMA LIMITED Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars SEP 2024 (Values in Cr)
Revenue 308.63
Operating Expense 263.65
Net Profit 63.20
Net Profit Margin (%) 20.47
Earnings Per Share (EPS) 1.39
EBITDA 83.64
Effective Tax Rate (%) 17.19
Particulars JUN 2024 (Values in Cr)
Revenue 254.53
Operating Expense 220.38
Net Profit 32.02
Net Profit Margin (%) 12.58
Earnings Per Share (EPS) 0.71
EBITDA 49.42
Effective Tax Rate (%) 24.30
Particulars MAR 2024 (Values in Cr)
Revenue 225.20
Operating Expense 198.98
Net Profit 32.99
Net Profit Margin (%) 14.64
Earnings Per Share (EPS) 0.73
EBITDA 46.09
Effective Tax Rate (%) 14.08
Particulars DEC 2023 (Values in Cr)
Revenue 241.36
Operating Expense 208.09
Net Profit 25.29
Net Profit Margin (%) 10.47
Earnings Per Share (EPS) 0.56
EBITDA 43.30
Effective Tax Rate (%) 26.90
Particulars SEP 2023 (Values in Cr)
Revenue 204.67
Operating Expense 176.10
Net Profit 31.29
Net Profit Margin (%) 15.28
Earnings Per Share (EPS) 0.69
EBITDA 53.23
Effective Tax Rate (%) 29.68
Particulars MAR 2024 (Values in Cr)
Revenue 853.27
Operating Expense 743.46
Net Profit 133.76
Net Profit Margin (%) 15.67
Earnings Per Share (EPS) 2.95
EBITDA 202.01
Effective Tax Rate (%) 22.18
Particulars MAR 2023 (Values in Cr)
Revenue 655.20
Operating Expense 583.65
Net Profit 102.87
Net Profit Margin (%) 15.70
Earnings Per Share (EPS) 2.48
EBITDA 152.39
Effective Tax Rate (%) 22.09
Particulars MAR 2022 (Values in Cr)
Revenue 658.29
Operating Expense 566.04
Net Profit 103.99
Net Profit Margin (%) 15.79
Earnings Per Share (EPS) 2.54
EBITDA 155.97
Effective Tax Rate (%) 22.68
Particulars MAR 2021 (Values in Cr)
Revenue 599.55
Operating Expense 506.38
Net Profit 98.38
Net Profit Margin (%) 16.40
Earnings Per Share (EPS) 2.40
EBITDA 144.87
Effective Tax Rate (%) 20.87
Particulars MAR 2020 (Values in Cr)
Revenue 433.42
Operating Expense 380.86
Net Profit 37.90
Net Profit Margin (%) 8.74
Earnings Per Share (EPS) 0.93
EBITDA 71.66
Effective Tax Rate (%) 28.10
Particulars MAR 2024 (Values in Cr)
Book Value / Share 45.57
ROE % 16.53
ROCE % 20.78
Total Debt to Total Equity 0.10
EBITDA Margin 23.38
Particulars MAR 2023 (Values in Cr)
Book Value / Share 38.51
ROE % 18.00
ROCE % 21.77
Total Debt to Total Equity 0.08
EBITDA Margin 21.52
Particulars MAR 2022 (Values in Cr)
Book Value / Share 27.10
ROE % 17.89
ROCE % 22.83
Total Debt to Total Equity 0.07
EBITDA Margin 20.17
Particulars MAR 2021 (Values in Cr)
Book Value / Share 21.66
ROE % 31.34
ROCE % 38.77
Total Debt to Total Equity 0.04
EBITDA Margin 25.16
Particulars MAR 2020 (Values in Cr)
Book Value / Share 15.54
ROE % 20.49
ROCE % 25.02
Total Debt to Total Equity 0.11
EBITDA Margin 16.98
Particulars MAR 2024 (Values in Cr)
Book Value / Share 26.98
ROE % 11.46
ROCE % 14.67
Total Debt to Total Equity 0.01
EBITDA Margin 23.67
Particulars MAR 2023 (Values in Cr)
Book Value / Share 24.52
ROE % 10.85
ROCE % 14.11
Total Debt to Total Equity 0.01
EBITDA Margin 23.26
Particulars MAR 2022 (Values in Cr)
Book Value / Share 16.90
ROE % 15.02
ROCE % 19.45
Total Debt to Total Equity 0.02
EBITDA Margin 23.69
Particulars MAR 2021 (Values in Cr)
Book Value / Share 14.65
ROE % 17.29
ROCE % 22.04
Total Debt to Total Equity 0.02
EBITDA Margin 24.16
Particulars MAR 2020 (Values in Cr)
Book Value / Share 12.35
ROE % 7.07
ROCE % 10.19
Total Debt to Total Equity 0.09
EBITDA Margin 16.53
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 673.57
Total Assets 2680.95
Total Liabilities 2680.95
Total Equity 2085.90
Share Outstanding 453163746
Price to Book Ratio 5.62
Return on Assets (%) 11.70
Return on Capital (%) 14.83
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 714.96
Total Assets 2190.38
Total Liabilities 2190.38
Total Equity 1765.07
Share Outstanding 453163746
Price to Book Ratio 2.87
Return on Assets (%) 12.15
Return on Capital (%) 14.74
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 349.26
Total Assets 1640.10
Total Liabilities 1640.10
Total Equity 1222.97
Share Outstanding 409313698
Price to Book Ratio 2.70
Return on Assets (%) 11.25
Return on Capital (%) 14.6
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 212.18
Total Assets 1228.81
Total Liabilities 1228.81
Total Equity 905.35
Share Outstanding 409313698
Price to Book Ratio 3.41
Return on Assets (%) 19.20
Return on Capital (%) 25.53
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 93.72
Total Assets 902.66
Total Liabilities 902.66
Total Equity 649.12
Share Outstanding 409313698
Price to Book Ratio 1.13
Return on Assets (%) 13.37
Return on Capital (%) 18.08
Particulars MAR 2024 (Values in Cr)
Net Income 423.52
Cash from Operations 352.75
Cash from Investing -140.84
Cash from Financing -68.72
Net change in Cash 20.84
Free Cash Flow 561.59
Particulars MAR 2023 (Values in Cr)
Net Income 337.65
Cash from Operations 300.42
Cash from Investing -259.21
Cash from Financing 197.82
Net change in Cash 176.02
Free Cash Flow 354.05
Particulars MAR 2022 (Values in Cr)
Net Income 247.51
Cash from Operations 172.11
Cash from Investing -84.39
Cash from Financing 79.51
Net change in Cash 94.37
Free Cash Flow 218.44
Particulars MAR 2021 (Values in Cr)
Net Income 302.16
Cash from Operations 227.12
Cash from Investing -44.84
Cash from Financing -15.28
Net change in Cash 118.45
Free Cash Flow 273.54
Particulars MAR 2020 (Values in Cr)
Net Income 157.17
Cash from Operations 258.32
Cash from Investing -59.58
Cash from Financing -113.55
Net change in Cash 60.18
Free Cash Flow 318.23
Particulars MAR 2024 (Values in Cr)
Net Income 171.89
Cash from Operations 72.81
Cash from Investing -114.22
Cash from Financing -26.21
Net change in Cash -106.38
Free Cash Flow 228.48
Particulars MAR 2023 (Values in Cr)
Net Income 132.03
Cash from Operations 83.34
Cash from Investing -194.62
Cash from Financing 210.01
Net change in Cash 67.12
Free Cash Flow 118.62
Particulars MAR 2022 (Values in Cr)
Net Income 134.50
Cash from Operations 87.80
Cash from Investing -128.06
Cash from Financing 70.86
Net change in Cash -1.23
Free Cash Flow 110.65
Particulars MAR 2021 (Values in Cr)
Net Income 124.33
Cash from Operations 127.13
Cash from Investing 8.87
Cash from Financing -13.53
Net change in Cash 102.26
Free Cash Flow 148.13
Particulars MAR 2020 (Values in Cr)
Net Income 52.72
Cash from Operations 118.06
Cash from Investing -24.14
Cash from Financing -81.87
Net change in Cash 1.55
Free Cash Flow 142.47
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 64.13 36.86 3.50 491.45 37.54 / 77.70
BLISS GVS PHARMA LTD 175.85 22.01 1.83 1852.87 92.25 / 179.65
CIPLA LTD 1447.35 25.32 4.12 116889.80 1192.85 / 1702.00
FERMENTA BIOTECH LIMITED 403.70 140.17 4.09 1188.13 145.00 / 440.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 64.13 55.77 10.90 491.45 37.54 / 77.70
AMRUTAJAN HEALTH LTD 749.90 45.61 7.28 2168.01 556.05 / 861.40
ASTRAZENECA PHARMA IND LT 6603.60 128.25 24.30 16509.00 4050.15 / 8139.85
BLISS GVS PHARMA LTD 175.85 22.93 1.80 1852.87 92.25 / 179.65

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 319.40
  • 26 Days 321.00
  • 10 Days 327.70
  • 50 Days 311.70
  • 12 Days 329.80
  • 100 Days 279.30
  • 20 Days 325.30
  • 200 Days 169.90
314.67
PIVOT
First Resistance 320.33
Second Resistance 330.17
Third Resistance 335.83
First Support 304.83
Second Support 299.17
Third Support 289.33
RSI 46.03
MACD 8.81
Commodity Channel Index (CCI) -69.36
ADX 46.04
Williams % R -89.85

Over 1 Month

down

2.14

Over 3 Months

down

12.46

Over 6 Months

down

96.85

Over 1 Year

down

92.92

Over 3 Years

down

72.01

Over 5 Years

down

85.41

MARKSANS PHARMA LIMITED Future

Future: Price

25 May
0 100 200 300 400 500 600

Discount/Premium

25 May
0 1 2 3 4 5 6 7

Active Calls

25 May
0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul
0 500 1000 1500 2000 2500

MARKSANS PHARMA LIMITED Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Public
30.71
Promoter Holdings
43.87
FII
21.31
DII
4.1
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Mark Saldanha Shareholding of Promoter and Promoter Group 1.98491553E8 43.8
Orbimed Asia Iv Mauritius Fvci Limited Public Shareholding 4.9324324E7 10.88
Massachusetts Institute Of Technology Public Shareholding 1.05E7 2.32
Uti Small Cap Fund Public Shareholding 6857881.0 1.51
Sandra Saldanha Shareholding of Promoter and Promoter Group 330456.0 0.07

MARKSANS PHARMA LIMITED

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2023-06-07 0.5 Final 2023-06-07 Equity shares 2022-08-19 0.25 Final 2022-08-23 Equity shares 2021-09-15 0.25 Final 2021-09-17 Equity shares 2020-09-22 0.1 Final 2020-09-24 Equity shares 2019-09-19 0.05 Final 2019-09-21 Equity shares 2018-09-19 0.05 Final 2018-09-22 Equity shares 2017-09-19 0.05 Final 2017-09-21 Equity shares 2016-09-22 0.12 Final 2016-09-24 Equity shares 2015-09-23 0.12 Final 2015-09-26 Equity shares 2014-09-18 0.1 Final 2014-09-20 Equity shares
Ex-Date Ex-Bonus Ratio
Ex-Date Old FV NEW FV Record Date
2008-03-11 10.0 1.0 2008-03-18

Marksans Pharma Share Result Highlights

Particulars

Sep 2024 (₹ in Cr)

Jun 2024 (₹ in Cr)

Mar 2024 (₹ in Cr)

Dec 2023 (₹ in Cr)

Sep 2023 (₹ in Cr)

Revenue

308.63

254.53

225.20

241.36

204.67

Operating Expense

263.65

220.38

198.98

208.09

176.10

Net Profit

63.20

32.02

32.99

25.29

31.29

Net Profit Margin (%)

20.47

12.58

14.64

10.47

15.28

Earnings Per Share (₹)

1.39

0.71

0.73

0.56

0.69

EBITDA

83.64

49.42

46.09

43.30

53.23

Effective Tax Rate (%)

17.19

24.30

14.08

26.90

29.68

Key Highlights:

  • Revenue Growth: Revenue grew significantly in Sep 2024 to ₹308.63 Cr from ₹204.67 Cr in Sep 2023.
  • Strong Profit Performance: Net profit increased to ₹63.20 Cr with a 20.47% margin.
  • Earnings Per Share (EPS): The EPS surged to ₹1.39 in Sep 2024.
  • Operating Efficiency: Operating expenses grew slower than revenue, improving margins.
  • The Marksans Pharma share price has shown positive results, reflecting the growth in key financial metrics.

Marksans Pharma Share Annual Reports

Particulars

Mar 2024 (₹ in Cr)

Mar 2023 (₹ in Cr)

Revenue

853.27

732.00

Operating Expense

743.46

650.23

Net Profit

133.76

112.65

Net Profit Margin (%)

15.67

15.39

Earnings Per Share (₹)

2.95

2.50

EBITDA

202.01

180.52

Effective Tax Rate (%)

22.18

20.50

Key Highlights:

  • Revenue Growth: Revenue increased by approximately ₹121.27 Cr from ₹732.00 Cr in FY 2022-23.
  • Profitability: The net profit grew to ₹133.76 Cr in FY 2023-24 with a 15.67% margin.
  • Strong EPS Performance: Earnings per share rose to ₹2.95.
  • Operational Efficiency: EBITDA grew by ₹21.49 Cr, reflecting improved operational efficiency.
  • The annual financial performance has had a positive impact on the Marksans Pharma share price, reflecting steady growth in revenue and profits.

Marksans Pharma Share Dividend

Particulars

Ex-Date

Record Date

Dividend per Share (₹)

07 Jun, 2023

07 Jun, 2023

Dividend Yield (%)

0.5

Equity Shares

Key Highlights:

  • Consistent Payouts: Marksans Pharma has regularly paid dividends, with the latest payout of ₹0.5 per share in June 2023.
  • Shareholder Returns: Dividend yields have been consistent, offering moderate returns to shareholders.
  • Final Dividends: Recent payouts have been final dividends, reflecting the company’s strong profit performance.
  • The dividend payouts complement the overall performance of the Marksans Pharma share price, providing additional value to investors.

About MARKSANS PHARMA LIMITED

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by MARKSANS PHARMA LIMITED

Learn More About Stocks

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Marksans Pharma Ltd?

Answer Field

The share price of Marksans Pharma Ltd for NSE is ₹ 312.25 and for BSE is ₹ 312.4.

What is the Market Cap of Marksans Pharma Ltd?

Answer Field

The market cap of Marksans Pharma Ltd for NSE is ₹ 1,41,50.04 Cr. and for BSE is ₹ 1,41,56.83 Cr. as of now.

What is the 52 Week High and Low of Marksans Pharma Ltd?

Answer Field

The 52 Week High and Low of Marksans Pharma Ltd for NSE is ₹ 358.70 and ₹ 130.00 and for BSE is ₹ 358.50 and ₹ 126.05.

How to Buy Marksans Pharma Ltd share?

Answer Field

You can trade in Marksans Pharma Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Marksans Pharma Ltd?

Answer Field

The 1 year returns on the stock has been 92.92%.

What is the Current Share Price of Marksans Pharma Ltd?

Answer Field

Marksans Pharma Ltd share price is for NSE ₹ 312.25 & for BSE ₹ 312.4 as on Dec 13 2024 03:30 PM.

What is the Market Cap of Marksans Pharma Ltd Share?

Answer Field

The market cap of Marksans Pharma Ltd for NSE ₹ 1,41,50.04 & for BSE ₹ 1,41,56.83 as on Dec 13 2024 03:30 PM.

What is the P/E Ratio of Marksans Pharma Ltd Share?

Answer Field

As on Dec 13 2024 03:30 PM the price-to-earnings (PE) ratio for Marksans Pharma Ltd share is 92.15.

What is the PB ratio of Marksans Pharma Ltd Share?

Answer Field

As on Dec 13 2024 03:30 PM, the price-to-book (PB) ratio for Marksans Pharma Ltd share is 28.48.

How to Buy Marksans Pharma Ltd Share?

Answer Field

You can trade in Marksans Pharma Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Marksans Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy Marksans Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Marksans Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Popular FAQs

Who is the CEO of Marksans Pharma Ltd?

Marksans Pharma Ltd is led by Mr. Mark Saldanha, who serves as the Managing Director and Chief Executive Officer of the company. Under his leadership, the company has expanded its presence in the global pharmaceutical market and achieved significant growth in various regions. Mr. Saldanha’s vision has been instrumental in driving the company’s strategic acquisitions, as well as in its research and development initiatives.

 

When was Marksans Pharma established?

Marksans Pharma Ltd was initially incorporated as Tasc Pharmaceuticals Limited in April 1982. Following a Scheme of Amalgamation, the company’s name was changed to Marksans Pharma Ltd on 10th October 2005. The rebranding marked the beginning of the company’s expanded focus on pharmaceutical formulations, and since then, it has become a prominent player in the pharmaceutical sector.

 

What factors influence the Marksans Pharma Share Price?

The Marksans Pharma share price is influenced by several key factors, including:

  • The company’s financial performance, including revenue growth, net profit, and earnings per share (EPS)
  • Acquisitions and R&D activities
  • Strong revenue and profit growth that boosts investor confidence
  • Successful product launches and US FDA approvals
  • Expanding R&D facilities
  • Broader pharmaceutical market trends and regulatory changes
  • Global economic factors impacting stock performance

 

Is Marksans Pharma debt-free?

Marksans Pharma Ltd is not entirely debt-free. However, the company has maintained a manageable level of debt as part of its capital structure. It strategically acquires businesses and invests in research and development to fuel its growth. The debt levels are often monitored to ensure they do not adversely impact the company's financial health. Despite this, the company has successfully maintained profitability and strong cash flow, helping it manage its liabilities efficiently.

 

What is the CAGR of Marksans Pharma Share?

The Marksans Pharma share price has demonstrated a Compound Annual Growth Rate (CAGR) of:

  • 20% over the last 10 years
  • 87% over the last 5 years
  • 72% over the last 3 years
  • 96% over the past year

This impressive growth rate highlights the company’s consistent performance and the market’s positive response to its strategic initiatives, including acquisitions and expanding its product portfolio.

 

How has the Marksans Pharma Share Price performed over the past year?

Over the past year, the Marksans Pharma share price has seen a remarkable increase of 96%. This surge in share price reflects strong financial performance, successful product approvals, and the company's continued expansion in both domestic and international markets. The robust growth in the past year has also been fueled by investor confidence, supported by strategic acquisitions such as Tevapharm India and the company's increasing presence in the global pharmaceutical industry.

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4700+ Cr MTF Book

icon-with-text
loader